PRESS-RELEASE filed Aug 12, 2026 at 16:02 ET
Kura Oncology reported Q1 2026 earnings with an EPS of -$0.83, beating consensus of -$0.88 by 5.7%, and revenue of $20.2M in line with estimates. The highlight is KOMZIFTI (ziftomenib) net product revenue of $9.1M, up 57% sequentially, with 115 new patient starts, up 35% sequentially, indicating strong commercial traction for its lead drug. The EPS beat is modest and the company remains pre-profitable, but the accelerating product revenue growth is the key positive signal for the stock.